3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
5
Phase 2
2
Phase 3
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Renal Cell
6
Carcinoma, Hepatocellular
3
Multiple Myeloma
2
Urothelial Cancer
1
Urologic Neoplasms
1
Stomach Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Kidney Neoplasms
1
Kidney Diseases
1
Gliosarcoma
1
Glioblastoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Adenocarcinoma Of Esophagus
1
Interventions
Cetuximab
44
Oxaliplatin
39
Irinotecan
38
Fluorouracil
36
Capecitabine
36
pembrolizumab
35
Leucovorin
35
Bevacizumab
35
Nivolumab
21
Gemcitabine
17
regorafenib
13
Panitumumab
12
IFL protocol
12
Folfox protocol
12
Cyclophosphamide
12
Pemetrexed
11
Cisplatin
11
tislelizumab
9
Paclitaxel
9
HMPL-013
9
Carboplatin
9
130-nm albumin-bound paclitaxel
8
durvalumab
7
Specimen Handling
7
Docetaxel
7
trametinib
6
Trifluridine
6
Ipilimumab
6
Drug Therapy
6
trifluridine tipiracil drug combination
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Colorectal Neoplasms
×
cabozantinib
×
Clear all
NCT03539822
2026-01-21
CAMILLA
University of Pittsburgh
Phase 1/2
Recruiting
117 enrolled